To include your compound in the COVID-19 Resource Center, submit it here.

vTv starts Phase Ib/II trial of TTP399 for T1D

vTv Therapeutics Inc. (NASDAQ:VTVT) began the Phase Ib/II simplici-T1 trial to evaluate TTP399 (GKI-399) as an add-on to insulin

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE